- NCIt
- C132146
Loading cancer entity…
Loading cancer entity…
Clinical trials
900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (101)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00728468 | A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients | completed | Phase 1 | 16 | PfizerINDUSTRY | 1 | Aug 2, 2017 | clinicaltrials |
| NCT00968981 | A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists | completed | Phase 1 | 67 | Genentech, Inc.INDUSTRY | 0 | Jul 11, 2017 | clinicaltrials |
| NCT01632696 | Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors | terminated | Early Phase 1 | 11 | Peregrine PharmaceuticalsINDUSTRY | 1 | Jul 11, 2017 | clinicaltrials |
| NCT00977067 | A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies | terminated | Phase 1 | 40 | Genentech, Inc.INDUSTRY | 0 | Jun 21, 2017 | clinicaltrials |
| NCT01670175 | Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors | completed | Phase 1 | 21 | University of California, San FranciscoOTHER | 1 | Jun 21, 2017 | clinicaltrials |
| NCT03171220 | Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors(NRT-01) | unknown | Phase 1 / Phase 2 | 40 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT00954642 | A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 24 | Genentech, Inc.INDUSTRY | 0 | May 17, 2017 | clinicaltrials |
| NCT03047811 | The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors | unknown | N/A | 15 | Fudan UniversityOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT01721148 | A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours | completed | Phase 1 | 39 | ASLAN PharmaceuticalsOTHER | 0 | Jan 25, 2017 | clinicaltrials |
| NCT02999750 | EXtendedAnalysis for Cancer Treatment | unknown | N/A | 55 | Medical University of ViennaOTHER | 1 | Dec 21, 2016 | clinicaltrials |
| NCT01611857 | Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach | completed | Phase 1 / Phase 2 | 49 | SCRI Development Innovations, LLCOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT00876109 | A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable | completed | Phase 1 | 108 | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01075464 | A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 64 | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01106599 | A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 61 | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01139723 | A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors | completed | Phase 1 | 54 | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01226277 | A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 42 | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01332604 | GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors | completed | Phase 1 | 41 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT01598129 | ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers | completed | Phase 1 | 12 | Targovax OyINDUSTRY | 1 | Oct 24, 2016 | clinicaltrials |
| NCT02884375 | Elderly CAncer Patient(ELCAPA) | recruiting | — | 3,000 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT01325558 | A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 30 | Altor BioScienceINDUSTRY | 1 | Jul 15, 2016 | clinicaltrials |
| NCT01090960 | A Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors | completed | Phase 1 | 52 | Genentech, Inc.INDUSTRY | 1 | Jul 4, 2016 | clinicaltrials |
| NCT02805166 | PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy | completed | Phase 4 | 420 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.INDUSTRY | 0 | Jun 17, 2016 | clinicaltrials |
| NCT01391533 | Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors(SARMET) | completed | Phase 1 | 72 | SanofiINDUSTRY | 4 | Apr 13, 2016 | clinicaltrials |
| NCT02096341 | A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001 | terminated | Phase 1 | 2 | EpicentRx, Inc.INDUSTRY | 1 | Jan 21, 2016 | clinicaltrials |
| NCT01694472 | Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors | unknown | Phase 1 | 15 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 22, 2015 | clinicaltrials |
| NCT00096941 | A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study | completed | Phase 2 | 3 | Genentech, Inc.INDUSTRY | 0 | Jun 11, 2015 | clinicaltrials |
| NCT01846429 | Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain | terminated | Phase 1 | 9 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00388427 | Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies | completed | Phase 1 | 31 | University of PittsburghOTHER | 1 | May 28, 2015 | clinicaltrials |
| NCT01343498 | Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors | completed | Phase 1 | 33 | SCRI Development Innovations, LLCOTHER | 1 | May 1, 2015 | clinicaltrials |
| NCT01567163 | A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors | completed | Phase 2 | 22 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 16, 2014 | clinicaltrials |
| NCT00884845 | Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors | completed | Phase 1 | 35 | PharmaMarINDUSTRY | 2 | Mar 26, 2014 | clinicaltrials |
| NCT01184807 | Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors | completed | Phase 1 | 51 | Otsuka Beijing Research InstituteINDUSTRY | 1 | Mar 26, 2014 | clinicaltrials |
| NCT00725634 | A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma(P05538) | completed | Phase 1 | 41 | AVEO Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 27, 2014 | clinicaltrials |
| NCT00337376 | A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers | terminated | Phase 1 | 23 | Yale UniversityOTHER | 1 | Jan 14, 2014 | clinicaltrials |
| NCT00551096 | Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors | completed | Phase 1 | 23 | University of Colorado, DenverOTHER | 1 | Dec 25, 2013 | clinicaltrials |
| NCT01951846 | To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours | completed | Phase 1 | 61 | Boehringer IngelheimINDUSTRY | 1 | Sep 27, 2013 | clinicaltrials |
| NCT00635791 | Phase I Study of Vorinostat and Sorafenib in Advanced Cancer | completed | Phase 1 | 36 | University of Colorado, DenverOTHER | 1 | Jun 20, 2013 | clinicaltrials |
| NCT00907205 | A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors(SF112600106) | completed | Phase 1 | 44 | Semafore PharmaceuticalsINDUSTRY | 1 | Jun 13, 2013 | clinicaltrials |
| NCT00925743 | A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer | completed | Phase 1 | 76 | SanofiINDUSTRY | 1 | May 16, 2013 | clinicaltrials |
| NCT01380249 | PDM08 Clinical Trial in Advanced Solid Tumors | completed | Phase 1 | 22 | Prodimed S.A.OTHER | 1 | Jan 7, 2013 | clinicaltrials |
| NCT01416623 | A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies | terminated | Phase 1 | 44 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 21, 2012 | clinicaltrials |
| NCT00969410 | A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases | completed | Phase 1 | 19 | AVEO Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 12, 2012 | clinicaltrials |
| NCT00747734 | A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 35 | Genentech, Inc.INDUSTRY | 0 | Apr 20, 2011 | clinicaltrials |
| NCT01019941 | Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer(126ASC08Q) | completed | Phase 1 | 44 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Dec 16, 2010 | clinicaltrials |
| NCT00516438 | Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan | completed | Phase 1 | 48 | AstraZenecaINDUSTRY | 1 | Dec 8, 2010 | clinicaltrials |
| NCT00478101 | Opioid Rotation Versus Combination for Chronic Uncontrolled Cancer Pain | completed | Phase 2 | 2,006 | Gachon University Gil Medical CenterOTHER | 0 | Mar 13, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Aug 2, 2017source: clinicaltrials